Anti-factor H antibody-positive C3 glomerulonephritis secondary to poststreptococcal acute glomerulonephritis with diabetic nephropathy.

Anti-factor H antibody C3 glomerulonephritis Diabetes mellitus Infection-related glomerulonephritis Poststreptococcal glomerulonephritis

Journal

CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244

Informations de publication

Date de publication:
15 Jul 2023
Historique:
received: 11 11 2022
accepted: 05 07 2023
medline: 15 7 2023
pubmed: 15 7 2023
entrez: 15 7 2023
Statut: aheadofprint

Résumé

Poststreptococcal acute kidney glomerulonephritis (PSAGN) has been seen in adults in recent years, especially in patients with type 2 diabetes mellitus, and the renal prognosis has not always been good. There have been cases of PSAGN in which complete remission was not achieved and hematuria and proteinuria persisted, leading to end-stage renal disease. Previous reports showed that the patients subjected to PSAGN have an underlying defect in regulating the alternative pathway of complement, and they identified that antibodies to the C3 convertase, C3 nephritic factors (C3NeF), are involved. C3NeF stabilizes C3 convertase, sustains C3 activation, and causes C3 glomerulonephritis (C3GN). On the other hand, factor H is a glycoprotein that suppresses the overactivation of the alternative pathway by decaying the C3 convertase. Anti-factor H (aFH) antibodies interfere with factor H and cause the same activation of the alternative pathway as C3NeF. However, a limited number of reports describe the clinical course of C3GN with aFH antibodies. We encountered a 49-year-old Japanese man with type 2 diabetes mellitus. He was referred to our hospital because of his elevated serum creatinine, proteinuria, hematuria, and developed edema on both legs. He was diagnosed as PSAGN at the first kidney biopsy, and his renal function improved and edema and hematuria disappeared, but proteinuria persisted after 5 months. He was diagnosed as C3GN at the second kidney biopsy. In our case, no C3NeF was detected. However, a high titer of aFH antibodies was detected in stored serum from the initial presentation, providing a unified diagnosis of aFH antibody-positive C3GN secondary to PSAGN. He progressed to end-stage renal disease (ESRD) and hemodialysis was started. The persistence of high levels of aFH autoantibodies may have caused C3GN secondary to PSAGN due to activating the alternative complement pathway, which eventually worsened the nephropathy and led to ESRD.

Identifiants

pubmed: 37452997
doi: 10.1007/s13730-023-00809-3
pii: 10.1007/s13730-023-00809-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s).

Références

Nasr SH, Radhakrishnan J, D’Agati VD. Bacterial infection-related glomerulonephritis in adults. Kidney Int. 2013;83:792–803.
doi: 10.1038/ki.2012.407 pubmed: 23302723
Nasr SH, Fidler ME, Valeri AM, Cornell LD, Sethi S, Zoller A, Stokes MB, Markowitz GS, D’Agati VD. Postinfectious glomerulonephritis in the elderly. J Am Soc Nephrol. 2011;22:187–95.
doi: 10.1681/ASN.2010060611 pubmed: 21051737
Pickering MC,DAgati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, et al. C glomerulopathy: consensus report. Kidney Int. 2013;84:1079–89.
doi: 10.1038/ki.2013.377 pubmed: 24172683
Oda T, Yoshizawa N, Yamakami K, Sakurai Y, Takechi H, Yamamoto K, Oshima N, Kumagai H. The role of nephritis-associated plasmin receptor (NAPlr) in glomerulonephritis associated with streptococcal infection. J Biomed Biotechnol. 2012;1:417675.
Oda T, Yoshizawa N, Yamakami K, Tamura K, Kuroki A, Sugisaki T, Sawanobori E, Higashida K, Ohtomo Y, Hotta O, Kumagai H, Miura S. Localization of nephritis-associated plasmin receptor in acute poststreptococcal glomerulonephritis. Hum Pathol. 2010;41:1276–85.
doi: 10.1016/j.humpath.2010.02.006 pubmed: 20708459
Dragon-Durey MA, Blanc C, Roumenina LT, et al. Anti-factor H antibodies assay. Methods Mol Biol. 2014;1100:249–56.
doi: 10.1007/978-1-62703-724-2_20 pubmed: 24218265
Barkai LJ, Sipter E, Csuka D, Prohaszka Z, Pilely K, Garred P, Hosszufalusi N. Decreased Ficolin-3-mediated complement lectin pathway activation and alternative pathway amplification during bacterial infections in patients with type 2 diabetes mellitus. Front Immunol. 2019;10:509.
doi: 10.3389/fimmu.2019.00509 pubmed: 30949171 pmcid: 6436462
Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15:129–43.
doi: 10.1038/s41581-018-0107-2 pubmed: 30692664 pmcid: 6876298
Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, Nasr SH, Smith RJ. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 2013;83:293–9.
doi: 10.1038/ki.2012.384 pubmed: 23235567
Dragon-Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anti-complement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016;12:563–78.
doi: 10.1038/nrneph.2016.99
Pilania RK, Bhattacharya D, Taneja N, Rawat A, Suri D, Ramachandran R, Tiewsoh K. Infection triggered anti complement factor H (CFH) positive atypical Hemolytic Uremic Syndrome in children: lessons for the clinical nephrologist. J Nephrol. 2021;34(3):943–7.
doi: 10.1007/s40620-020-00913-y pubmed: 33387343

Auteurs

Yuki Oba (Y)

Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Kawasaki, Kanagawa, 213-8587, Japan. pugpug.yuki008@gmail.com.

Hiroki Mizuno (H)

Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Kawasaki, Kanagawa, 213-8587, Japan.

Sekiko Taneda (S)

Department of Pathology, Tokyo Women's Medical University, 8-1 Kawada-Cho, Shinjuku-Ku, Tokyo, 162-8666, Japan.

Toshihiro Sawai (T)

Department of Pediatrics, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga, 520-2192, Japan.

Takashi Oda (T)

Department of Nephrology and Blood Purification, Tokyo Medical University Hachioji Medical Center, 1163 Tatemachi, Hachioji, Tokyo, 193-0998, Japan.

Daisuke Ikuma (D)

Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Kawasaki, Kanagawa, 213-8587, Japan.

Masayuki Yamanouchi (M)

Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Kawasaki, Kanagawa, 213-8587, Japan.

Tatsuya Suwabe (T)

Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Kawasaki, Kanagawa, 213-8587, Japan.

Kei Kono (K)

Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.

Keiichi Kinowaki (K)

Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.

Kenichi Ohashi (K)

Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-Ku, Tokyo, 105-8470, Japan.
Department of Human Pathology, Tokyo Medical Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.

Naoki Sawa (N)

Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Kawasaki, Kanagawa, 213-8587, Japan.

Yoshifumi Ubara (Y)

Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1 Kajigaya, Kawasaki, Kanagawa, 213-8587, Japan.

Classifications MeSH